| Michael Walton, MD | |
|
403 S 11th St Ste 210, Boise, ID 83702-6968 | |
| (208) 381-6005 | |
| Not Available |
| Full Name | Michael Walton |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 19 Years |
| Location | 403 S 11th St Ste 210, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114192028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 241298 (New York) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | M-14771 (Idaho) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes Clinic-treasure Valley Llc | 4981878402 | 968 |
News Archive
According to new research from the U.S. dog owners are more likely to share germs with pets by not washing their hands than by sleeping with the dog.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
Researchers in the UK have conducted a study suggesting that the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – is transmitted more quickly than previously circulating variants.
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
› Verified 1 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
According to new research from the U.S. dog owners are more likely to share germs with pets by not washing their hands than by sleeping with the dog.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
Researchers in the UK have conducted a study suggesting that the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – is transmitted more quickly than previously circulating variants.
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Walton, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: () - | Michael Walton, MD 403 S 11th St Ste 210, Boise, ID 83702-6968 Ph: (208) 381-6005 |
News Archive
According to new research from the U.S. dog owners are more likely to share germs with pets by not washing their hands than by sleeping with the dog.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
Researchers in the UK have conducted a study suggesting that the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – is transmitted more quickly than previously circulating variants.
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
› Verified 1 days ago
Dr. Michael E. Estess, M. D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1471 Shoreline Dr, Suite 119, Boise, ID 83702 Phone: 208-345-2630 Fax: 208-345-6504 | |
John Carr, PMHNP Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1000 N Curtis Rd Ste 202, Boise, ID 83706 Phone: 208-283-7314 | |
Eric A Simmons, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 335 Allumbaugh St, Boise, ID 83704 Phone: 208-376-1611 Fax: 208-658-1753 | |
Dr. Gary Falk, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 500 W Fort St, Boise Vamc, Boise, ID 83702 Phone: 208-422-1108 | |
Karen Porth, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1072 N Liberty Street, Ste 303, Boise, ID 83704 Phone: 208-367-2800 Fax: 208-367-7111 | |
Ramon R Quijano, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 W Fort St., Fl 2, Boise, ID 83702 Phone: 208-422-1018 | |
Barbara J. Hagen, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 413 Allumbaugh St Ste 101, Boise, ID 83704 Phone: 208-323-1125 Fax: 208-323-9604 |